COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00261937
Recruitment Status : Completed
First Posted : December 6, 2005
Last Update Posted : February 6, 2013
Information provided by:
Bnai Zion Medical Center

Brief Summary:
We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Condition or disease Intervention/treatment Phase
Bronchiolitis Drug: Inhaled Furosemide vs Placebo (Normal Saline) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants
Study Start Date : December 2005
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Furosemide

Primary Outcome Measures :
  1. Clinical respiratory effects

Secondary Outcome Measures :
  1. 1. The duration of hospitalization
  2. 2. Time weaned off oxygen
  3. 3. Time to full enteral feeding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 0-12 months.
  • Infants who are otherwise healthy
  • Infants with chronic lung disease of prematurity (BPD) will be included, but will be analyzed separately.
  • Parents signed a written informed consent.

Exclusion Criteria:

  • • Other previous or co-morbidity, specifically: respiratory (other than BPD, like Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00261937

Layout table for location information
Bnai Zion Medical Center and Naharia Galilli Medical Center
Haifa, Israel, 31048
Sponsors and Collaborators
Bnai Zion Medical Center
Layout table for investigator information
Principal Investigator: Amir Kugelman Bnai Zion Medical Center

Publications of Results:
Layout table for additonal information Identifier: NCT00261937    
Other Study ID Numbers: 67/05
First Posted: December 6, 2005    Key Record Dates
Last Update Posted: February 6, 2013
Last Verified: December 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis, Viral
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Virus Diseases
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action